(18)F-FDG PET in sarcoma treatment response imaging. - Wikidata - wikimedia - TriplyDB

(18)F-FDG PET in sarcoma treatment response imaging.

(18)F-FDG PET in sarcoma treatment response imaging.

http://www.wikidata.org/entity/Q36337223

about

Positron emission tomography imaging of atherosclerosis Antibody-based imaging of HER-2: moving into the clinic.PET/SPECT imaging of hindlimb ischemia: focusing on angiogenesis and blood flow.Evaluation of 68Ga-labeled MG7 antibody: a targeted probe for PET/CT imaging of gastric cancer.Positron Emission Tomography and Near-Infrared Fluorescence Imaging of Vascular Endothelial Growth Factor with Dual-Labeled Bevacizumab.Positron emission tomography and optical imaging of tumor CD105 expression with a dual-labeled monoclonal antibody.In vivo targeting and positron emission tomography imaging of tumor vasculature with (66)Ga-labeled nano-graphene Positron emission tomography imaging of tumor angiogenesis with a 66Ga-labeled monoclonal antibody.Graphene: a versatile nanoplatform for biomedical applications.ImmunoPET and near-infrared fluorescence imaging of CD105 expression using a monoclonal antibody dual-labeled with (89)Zr and IRDye 800CW.In a "nutshell": intrinsically radio-labeled quantum dots.Monitoring bone and soft-tissue tumors after carbon-ion radiotherapy using ¹⁸F-FDG positron emission tomography: a retrospective cohort study.Multimodality imaging of breast cancer experimental lung metastasis with bioluminescence and a monoclonal antibody dual-labeled with 89Zr and IRDye 800CW.Tumor vasculature targeting and imaging in living mice with reduced graphene oxide.Is PET-CT an accurate method for the differential diagnosis between chondroma and chondrosarcoma?Positron emission tomography imaging of vascular endothelial growth factor receptor expression with (61)Cu-labeled lysine-tagged VEGF121.Imaging tumor angiogenesis in breast cancer experimental lung metastasis with positron emission tomography, near-infrared fluorescence, and bioluminescence Quantum dot-based nanoprobes for in vivo targeted imaging.Multimodality imaging of CXCR4 in cancer: current status towards clinical translation.Biomedical applications of zinc oxide nanomaterials.Functionalized upconversion nanoparticles: versatile nanoplatforms for translational research Intraoperative targeted optical imaging: a guide towards tumor-free margins in cancer surgery.Multimodality imaging of RNA interference Peptoid and Positron Emission Tomography: an Appealing Combination A Review on Green Synthesis, Biomedical Applications, and Toxicity Studies of ZnO NPs

P2860

Q26824610-D2234DD8-6330-436C-9C99-938C6F691DC7 Q30423880-E1C76B0C-1B65-48EE-AF5D-3ED602CE7DF2 Q34464099-BFFB23AE-107C-4B91-9AFE-01CD6969B7C9 Q35138836-986A59E9-59AA-4323-8671-A7260552F347 Q35646547-A8A701A2-BE9A-4DB1-9134-AF65AB27F867 Q35809541-3F57B117-5C2C-4A93-8A10-62AF057C5E9B Q35854802-26699A9F-F033-4B96-A0BC-F09212E9714A Q36034526-ADB8A2D8-1EC5-4388-8601-9D62B19460E5 Q36035392-9824E779-6104-4832-A49F-EB122EFA0715 Q36185354-AF9E9D13-ADE8-4286-971B-CF48402D3CD7 Q36337263-19543BE3-7478-4383-A516-F38E684F5340 Q36393691-31F31DA0-AB01-45E0-81DA-BE1DDDD7AA0B Q36406701-063BEE04-DA54-4ECC-A098-24191E681B4D Q36604948-C035B143-3B3C-4F40-8F23-E811A02804DF Q36632352-DF553294-DD5C-409A-8FF2-378A9DEA0FEB Q36746567-467A13B3-D6CF-4ECE-BC2D-66576F107F69 Q36996613-C110BD51-A4DC-4964-A19D-26909912921E Q37337213-7A2F3FF2-F97E-4490-B08E-2831794AE1C3 Q37337280-F863CF45-F136-4926-B3F7-04A8B632BD5C Q37337342-28C1ACC0-CB5B-4B7A-8958-F32AEAB7314F Q37354263-40896ABE-141A-4623-8DA2-77FA6EADE5AE Q37624855-B0190592-052B-4C7D-9AB8-C581239AC69E Q38112726-F2EC8F93-918C-4361-AF83-7CB4884BF817 Q38595230-70B729E2-452D-424D-9407-72CFDD586824 Q58805835-97B95C40-1D8E-4B01-826D-2287C1B01491

P2860

(18)F-FDG PET in sarcoma treatment response imaging.

http://www.wikidata.org/entity/Q36337223

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

2011年學術文章

@zh

2011年學術文章

@zh-hant

name

(18)F-FDG PET in sarcoma treatment response imaging.

@ast

(18)F-FDG PET in sarcoma treatment response imaging.

@en

type

label

(18)F-FDG PET in sarcoma treatment response imaging.

@ast

(18)F-FDG PET in sarcoma treatment response imaging.

@en

prefLabel

(18)F-FDG PET in sarcoma treatment response imaging.

@ast

(18)F-FDG PET in sarcoma treatment response imaging.

@en

P1433

Q36337223-BD3311C7-6700-43A6-86AC-96526A3B659D

P1476

Q36337223-3F7F64B6-102B-4EE2-A9E2-1192E37D2710

P2093

Q36337223-29A18BC5-1AA0-4614-9CF7-1AAE546BAC50

Q36337223-3BBCA00F-C0F0-4CD3-B4FB-532C3006173D

Q36337223-847F1F52-3869-40DD-B697-217E6EE1BE02

Q36337223-BC08EC89-9DD8-4A85-8784-A4DC62104F04

P2860

Q36337223-017FAA52-2212-4A28-A29F-0181A7961158

Q36337223-0762F103-D3AC-4A48-800B-9B0BA20CBADB

Q36337223-0792582F-D51E-4E95-8C06-C804234A0978

Q36337223-080A9145-ADF4-4201-9371-43517F685F7F

Q36337223-08C11CAE-1749-4D74-9647-0688FB7B9D4F

Q36337223-1F672C1A-66F4-48C6-8AEA-5AFB5C25AEF5

Q36337223-1F75BE41-BB86-4BA7-87A0-9727DAA546AA

Q36337223-25ACD24E-52F8-4E3D-8B83-4D51D9AF7B51

Q36337223-290ACEE3-5AE6-4356-97AF-A51297AFCF30

Q36337223-3D8F4248-230A-4302-8A52-94E0A095065F

P304

Q36337223-A7D2A8C0-0B1C-43B1-80EF-3201AE1810A8

P31

Q36337223-D3CDA9B4-5791-4A44-8E2C-C6BD0CEEB6DE

P433

Q36337223-37572350-3DF8-4BEA-B1AD-9A0172A8B3BE

P478

Q36337223-0D5B134C-97BA-4E76-849C-12F94B8B55F0

P577

Q36337223-D1D874C0-6EBD-4BDE-A5DD-B6B7B3DF5AC2

P698

Q36337223-1C6299DE-C6F5-4C68-98A1-F0CC35DB9872

P932

Q36337223-156713D2-A87F-4557-93EC-B61481A48A4E

P1433

American journal of nuclear medicine and molecular imaging

P1476

(18)F-FDG PET in sarcoma treatment response imaging

@en

P2093

Douglas S Hawkins

http://www.w3.org/2001/XMLSchema#string

Ernest U Conrad

http://www.w3.org/2001/XMLSchema#string

Eve T Rodler

http://www.w3.org/2001/XMLSchema#string

Janet F Eary

http://www.w3.org/2001/XMLSchema#string

P2860

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development

Combined assessment of metabolic and volumetric changes for assessment of tumor response in patients with soft-tissue sarcomas.

A randomized, phase II study of preoperative plus postoperative imatinib in GIST: evidence of rapid radiographic response and temporal induction of tumor cell apoptosis.

RECIST revisited: a review of validation studies on tumour assessment.

Use of positron emission tomography in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumors (GISTs).

Assessment of therapy response by FDG PET in pediatric patients.

Functional imaging techniques for evaluation of sarcomas.

Mechanisms of sarcoma development.

Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO.

P304

47-53

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

1

http://www.w3.org/2001/XMLSchema#string

P577

2011-06-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23133794

http://www.w3.org/2001/XMLSchema#string

P932

3477719

http://www.w3.org/2001/XMLSchema#string